Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia - Test2 - elhamkhani - TriplyDB

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

http://www.wikidata.org/entity/Q29620690

about

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib Role of the tumor microenvironment in mature B-cell lymphoid malignancies Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas Chronic lymphocytic leukemia: a clinical review including Korean cohorts Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia Current concepts in diagnosis and treatment of chronic lymphocytic leukemia TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia Ibrutinib The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia Management of Chronic Lymphocytic Leukemia in the Elderly PI3K and AKT: Unfaithful Partners in Cancer Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)Lymphoma Immunotherapy: Current Status Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective Myeloid Cells as Targets for Therapy in Solid Tumors Predictive biomarkers in precision medicine and drug development against lung cancer New strategies in chronic lymphocytic leukemia: shifting treatment paradigms Ten things you should know about protein kinases: IUPHAR Review 14 Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib Targeted therapies in CLL: mechanisms of resistance and strategies for management B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292 High-dimensional single-cell cancer biology How will B-cell-receptor-targeted therapies change future CLL therapy?Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review AACR Cancer Progress Report 2014 The tumor microenvironment shapes hallmarks of mature B-cell malignancies.Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

P2860

Q26741998-A1C17336-0A60-413F-AB65-C23C212BDAE5 Q26744277-84EECFC9-B189-44BD-8B22-C43C46C18B55 Q26748775-FE5A11EC-6945-4A7E-BE2A-8B969BB56C20 Q26749010-B551A25A-DE7C-4A5F-B206-D0290418176B Q26749139-1FD47461-6C71-4693-8947-153D124FC94F Q26752467-6D72CFE2-E62E-4E4B-9C33-904CC29964B6 Q26764833-198FE934-9E4F-44C2-A201-BB909FBFECDB Q26765624-4F23BA6D-2243-4B3C-A0F5-990D3F2B9D4F Q26770471-5CB02ADF-DCCC-426F-B2D8-0D3CFFCBBB5D Q26773053-DF670DD5-848C-4AE6-AC41-621E00975A71 Q26773236-D6C8D241-DF39-4401-B416-EE52B72426F8 Q26775506-1790594D-8056-4A10-83B1-9DD1A1FB0D36 Q26775983-F0888549-191B-448F-891E-C3C0975D96C8 Q26781367-70302C56-3EE7-434C-A1CB-85E160F54258 Q26781895-F16E3E51-023C-40CB-9F5F-F6B1251736EB Q26782270-12478A50-7CA8-4919-A93C-BAB507D8E3E1 Q26782633-BBC6B65C-A86F-4C65-BE28-43691AB8FB32 Q26782902-914C636C-22AB-41F0-9889-2CF8346A44A2 Q26783430-DE558931-FF83-4BB5-B38C-51BC9712D6DC Q26785497-0BF62014-5A85-46A7-82BA-735615296246 Q26795594-1875EBED-8A89-4947-9677-EF7A25569003 Q26796455-9B4D21B1-779D-45E8-ACF7-C2DFCFFAD4B2 Q26801832-6568D4C2-57AD-403A-BFB1-3E784C2BFE98 Q26824536-5835BC37-DB0C-4AD8-89EE-5E50B865A931 Q26828496-699864C1-EAB9-48A5-ADC0-6363E0DA0553 Q26849417-0BD1A9B2-8DAC-462C-82DE-690EBADBDB9F Q26851417-77377B5F-174F-46DF-95E1-C27B3866F56F Q26865760-31827CC6-9080-4E9F-8E91-B616F3FDB10E Q26991890-5210A561-9C7E-410A-A446-90B39E122B6E Q26995113-819CBFA6-8A79-45FB-A441-8B09B565A34D Q27002528-0A398AC6-DA88-45A2-85FA-C2407C314236 Q27009550-F7F3D09F-22C9-49A2-B76C-1D2222150849 Q27021173-97D56FC6-2A57-42B7-AE59-299BD75994E9 Q27024187-FB7FEE82-7E74-47FC-91A1-3B0A82BB1133 Q27025812-D65844A9-08B9-45E3-9327-0E9E1BC6E381 Q27026912-A1FCB9B5-EBD4-4991-87E2-C15F57DBAC78 Q27304386-5DC9DCD7-CE9A-4E02-9A40-BA49D6150207 Q27346723-7CCFC29E-63B5-4335-8A10-4EC851E85C49 Q27687567-7D645514-2341-427C-82C7-7F04C9F6C58C Q27853011-E6AC104E-0228-4852-B2DD-6FBB18A9C958

P2860

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

http://www.wikidata.org/entity/Q29620690

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

@ast

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

@en

type

label

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

@ast

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

@en

prefLabel

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

@ast

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

@en

P1433

Q29620690-D8E40912-0A61-4629-9045-2351F3797A23

P1476

Q29620690-723D7334-6CAE-467B-B220-6D33F7C17498

P2093

Q29620690-06ED1EA3-EC48-4A1A-8659-588DA9069583

Q29620690-4432868B-620B-4B49-8C6D-67F81567212C

Q29620690-4E33EDF5-081E-41AF-AF63-4D06A08E8392

Q29620690-56013B49-C0A7-4407-9323-526E08993BC5

Q29620690-588D5711-0D78-4FA8-A8B6-8DC13A4C6BC9

Q29620690-58CBA9D7-B3D3-4028-A023-A0A56234A5F5

Q29620690-5F0B0522-6524-4101-8B0B-9F2C66A605FF

Q29620690-7EFB5EB4-161B-4BD4-B5D0-AAD1BFE0C146

Q29620690-8C57111A-ABA3-47AC-B764-D51F9FA931BD

Q29620690-99B1EB8A-A799-4FB9-9328-E9479AEE3B72

P2860

Q29620690-01C707AF-1BE3-48D2-8BE5-4DA1BDB72C62

Q29620690-06F1C863-AC05-40DE-A6EB-D613F3ED3923

Q29620690-0D9DFBD1-423D-4E95-9B98-AF32659D3E0A

Q29620690-1C501A1B-AE20-4B29-AE4F-E8C9B99790CC

Q29620690-249775A8-F2BF-4B1C-A605-991D338CB203

Q29620690-34F643F9-7F25-4C98-B717-6D6BF05597E9

Q29620690-35C3D9CB-8302-432A-8331-0AE7EC8BDB4C

Q29620690-3D97B872-026F-4D8F-ABA9-67DEB7B92EF0

Q29620690-4E52E53A-7F1B-4353-98A5-42CBEA0D8D2B

Q29620690-548E1AD5-8589-4036-9621-494EE57754F3

P304

Q29620690-41B90394-0A1C-412C-8A1E-661CA2F4DAD7

P31

Q29620690-CBF01C12-0906-4066-97FC-134451F7DD71

P3181

Q29620690-A7F255A4-0D34-4448-B9FB-77A28747549C

P356

Q29620690-D77DFC33-D5B7-4B70-9826-ACF1BBDA0648

P407

Q29620690-7CEF62BF-DA20-41D3-A233-DD912F493DE8

P433

Q29620690-8EA6D27E-6685-45B8-8516-2B5D42A8313A

P478

Q29620690-7553BE7F-D39B-479A-ACE0-E598ECFB1481

P50

Q29620690-06C60063-8C69-4D85-8EB1-2D436582B62C

Q29620690-F1B25264-3A0D-47CF-B581-6C63C54AFFD3

P577

Q29620690-E31F4825-7828-4D1C-B238-04F975430573

P5875

Q29620690-C55C1EDE-2428-45B9-BFD4-CC7908BC6DA2

P698

Q29620690-5DDDCC3D-280C-4371-B1AF-3C1F794D65CF

P921

Q29620690-3D0330DD-63BF-47FF-B7D6-F024C1A8E5EC

Q29620690-ABFB4D40-8571-4952-84DD-65767A1829D5

Q29620690-B4D68B65-4452-41DB-A73A-E4A9BB9B0311

P932

Q29620690-0D37C21C-4242-49BC-9492-911EF4B4C57A

P3181

P356

P1433

The New England Journal of Medicine

P1476

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

@en

P2093

Amy J Johnson

http://www.w3.org/2001/XMLSchema#string

Barbara Grant

http://www.w3.org/2001/XMLSchema#string

Betty Y Chang

http://www.w3.org/2001/XMLSchema#string

Danelle F James

http://www.w3.org/2001/XMLSchema#string

Eric Hedrick

http://www.w3.org/2001/XMLSchema#string

Fong Clow

http://www.w3.org/2001/XMLSchema#string

Jan A Burger

http://www.w3.org/2001/XMLSchema#string

Jeff P Sharman

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Jones

http://www.w3.org/2001/XMLSchema#string

John C Byrd

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells

Chronic lymphocytic leukemia

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Classification of lymphoid neoplasms: the microscope as a tool for disease discovery.

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

P304

32-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

8410

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1215637

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

239940906

http://www.w3.org/2001/XMLSchema#string

P698

23782158

http://www.w3.org/2001/XMLSchema#string

P921

P932

3772525

http://www.w3.org/2001/XMLSchema#string